When it comes to maintaining clean equipment for making medicines, one drug maker recently danced around the issue.

During an inspection of a Centurion Laboratories facility in India last October, a Food and Drug Administration investigator noticed a variety of troubling manufacturing problems. These included a failure to follow written procedures for cleaning and maintaining equipment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Then they are out of compliance with Part 11 along with the common sense items that they overlooked as well.

  • At least the company did not truly ‘dance around the truth’ when it came to the cleaning issues. The forms torn to “avoid confusing the investigator,” perhaps not so much?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy